期刊
CURRENT MEDICINAL CHEMISTRY
卷 16, 期 29, 页码 3841-3857出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986709789178046
关键词
Angiotensin II; heart; losartan; renin-angiotensin system; cardiac remodeling; hypertension
资金
- NIH [HL82779, HL83966, HL090920]
- NSFC [30871400]
- Jiangsu NSF [BK2006703, 08KJB32001]
- Suzhou [SZS0602, EE134704]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089012, R01HL083966, R01HL090920, R01HL082779] Funding Source: NIH RePORTER
The renin-angiotensin system (RAS) plays an important role in the homeostasis of the cardiovascular system and in the development of cardiovascular diseases. An abnormal expression or over activation of the local RAS in the heart and vasculature system is one of the most common mechanisms in pathophysiological processes in cardiovascular diseases. This also provides a basis for medical prevention and treatments using chemical approaches. Losartan is a selective nonpeptite antagonist against type 1 angiotensin II receptors (AT1R), and has been applied in medical treatments of a variety of cardiovascular diseases, including essential hypertension. This article reviews direct and indirect cardiovascular effects of losartan on the heart and blood vessels. It summarizes the chemical basis of AT1R for the action site of losartan, focuses on the mechanisms underlying the action of losartan involved in both the heart and vasculature, and reviews the information that may be helpful in the development of new chemical candidates or approaches in the war against cardiovascular diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据